DK1015026T3 - IL-12 som en adjuvans til Bordetella pertussis-vacciner - Google Patents

IL-12 som en adjuvans til Bordetella pertussis-vacciner

Info

Publication number
DK1015026T3
DK1015026T3 DK97932137T DK97932137T DK1015026T3 DK 1015026 T3 DK1015026 T3 DK 1015026T3 DK 97932137 T DK97932137 T DK 97932137T DK 97932137 T DK97932137 T DK 97932137T DK 1015026 T3 DK1015026 T3 DK 1015026T3
Authority
DK
Denmark
Prior art keywords
adjuvant
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Application number
DK97932137T
Other languages
Danish (da)
English (en)
Inventor
Kingston H G Mills
Bernard P Mahon
Mark S Ryan
Fiona Griffin
Original Assignee
Nat Univ Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth
Application granted granted Critical
Publication of DK1015026T3 publication Critical patent/DK1015026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97932137T 1996-05-31 1997-05-30 IL-12 som en adjuvans til Bordetella pertussis-vacciner DK1015026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1587196P 1996-05-31 1996-05-31
US82986597A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
DK1015026T3 true DK1015026T3 (da) 2006-09-11

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97932137T DK1015026T3 (da) 1996-05-31 1997-05-30 IL-12 som en adjuvans til Bordetella pertussis-vacciner

Country Status (10)

Country Link
US (5) US6929794B1 (de)
EP (2) EP1649868A1 (de)
JP (2) JP3737519B2 (de)
AT (1) ATE325621T1 (de)
AU (1) AU724743B2 (de)
DE (1) DE69735856T2 (de)
DK (1) DK1015026T3 (de)
ES (1) ES2262181T3 (de)
PT (1) PT1015026E (de)
WO (1) WO1997045139A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
IL137809A0 (en) * 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
EP1058557A1 (de) * 1998-03-05 2000-12-13 The Medical College Of Ohio Steigerung der immunität durch intranasale verabreichung von il-12
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
AU2001270031B2 (en) * 2000-06-22 2005-11-03 Wyeth Holdings Corporation QS-21 and IL-12 as an adjuvant combination
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
PL2670432T3 (pl) * 2011-02-04 2021-10-11 Zoetis Services Llc Kompozycje immunogenne Bordetella bronchiseptica
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
ATE140483T1 (de) 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
JP3485184B2 (ja) * 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
CA2139948C (en) 1992-07-13 2001-12-04 Fred D. Ledley Targeting somatic gene therapy to joints
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
JPH10502366A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
WO1996010423A1 (en) 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
DK0784486T3 (da) * 1994-10-05 2006-08-14 Univ Vanderbilt Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines

Also Published As

Publication number Publication date
EP1015026A2 (de) 2000-07-05
PT1015026E (pt) 2006-08-31
JP3737519B2 (ja) 2006-01-18
DE69735856D1 (de) 2006-06-14
JP2005112865A (ja) 2005-04-28
EP1015026B1 (de) 2006-05-10
WO1997045139A3 (en) 1998-02-12
AU3567097A (en) 1998-01-05
US20060263380A1 (en) 2006-11-23
WO1997045139A2 (en) 1997-12-04
EP1649868A1 (de) 2006-04-26
ATE325621T1 (de) 2006-06-15
ES2262181T3 (es) 2006-11-16
US20060263379A1 (en) 2006-11-23
US20050158276A1 (en) 2005-07-21
US20060257419A1 (en) 2006-11-16
JP2001527516A (ja) 2001-12-25
AU724743B2 (en) 2000-09-28
DE69735856T2 (de) 2006-11-16
US6929794B1 (en) 2005-08-16

Similar Documents

Publication Publication Date Title
DK1015026T3 (da) IL-12 som en adjuvans til Bordetella pertussis-vacciner
FI913820L (fi) Traodlikt hemagglutinin fraon bordetella pertussis som baerarmolekyl foer konjugatvaccin.
KR950702125A (ko) 보조약을 함유하는 백신 조성물(vaccine composition containing adjuvants)
NL300400I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
ATE284710T1 (de) Adjuvans für vitale impfstoffe
FI913350A7 (fi) Bordetella pertussiksen vastaisia tehokkaita rokotteita, jotka koostuvat erikseen puhdistettujen pertussis-antigeenien yhdistelmästä
NZ513202A (en) Antigen composition comprising Bordetella bronchiseptica, formalin and glutaraldehyde
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
DE69420740D1 (de) Fluorkautschukzusammensetzung und masse daraus
DK0745388T3 (da) Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans
DK1049488T3 (da) Fremgangsmåde og præparat til immunisering med Pseudomonas aeruginosa-V-antigenet
TW275632B (de)
DE69131525D1 (de) Pasteurella multocida toxoid enthaltende impfstoffe
DK355789D0 (da) Bordetella pertussis vaccine
FR2594714B1 (fr) Dispositif distributeur-diffuseur de substances volatiles, notamment de desodorisants d'atmosphere
ES2136443T3 (es) Limpieza in situ.
ITMI910371U1 (it) Canaletta ecologica per la risagomatura di fossi, o similari, e per la correzione della pendenza di questi ultimi
DE69128095D1 (de) Azelluläre impfstoffe
FR2762787B1 (fr) Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények
ITVI910034A1 (it) Manipolo pneumatico per microsabbiatrici e sabbiatrici o simili.
TR28707A (tr) Oda spreyi yayma düzenegi.
ITTO940719A0 (it) Dispositivo per l'abbattimento di polveri provocate dalla perforazionedi pietra e simili.
KR950015415U (ko) 디스크 드라이브(disk drive) 고정장치
ITUD930145A1 (it) Chiave dinamometrica per implantologia ossea